PATRICK COLLINS

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--To amend title XVIII of the Social Security Act to provide for coverage and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under part B of such title, and for other purposes. Coverage for alpha 1 proteinase inhibitor and its administration in the home under Medicare Part B. S 1281, HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act--Medicare Part D restructure, direct negotiation of Medicare pricing, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in a scaled back version of BBBA.

Education efforts surrounding hemophilia B and a new gene therapy treatment that CSL Behring submitted to FDA for licensure HR 5376--Inflation Reduction Act--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of Build Back Better Act. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of Prescription Drug User Fee Act VII specific to FDA user fees.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

HR 5376--Inflation Reduction Act--Sought to have language stricken that would limit the Orphan Drug Tax Credit to solely the first product indication for a therapy. Also sought to include language that would delay the requirement to amortize Research & Development expenses over 5 years instead of obtaining an immediate deduction from taxable income.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--To amend title XVIII of the Social Security Act to provide for coverage and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under part B of such title, and for other purposes. Coverage for alpha 1 proteinase inhibitor and its administration in the home under Medicare Part B. S 1281, HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act--Medicare Part D restructure, direct negotiation of Medicare pricing, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in a scaled back version of BBBA.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

Education efforts surrounding hemophilia B and a new gene therapy treatment that CSL Behring submitted to FDA for licensure HR 5376--Inflation Reduction Act--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of Build Back Better Act. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of Prescription Drug User Fee Act VII specific to FDA user fees.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

Education efforts surrounding hemophilia B and a new gene therapy treatment that CSL Behring submitted to FDA, which has been licensed. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. HR 2617--Consolidated Appropriations Act 2023--Discussion of health policy riders within the legislation, including language surrounding the accelerated approval pathway and clinical trial diversity.

Education efforts surrounding hemophilia B and a new gene therapy treatment that CSL Behring submitted to FDA for licensure HR 5376--Inflation Reduction Act--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of Build Back Better Act. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of Prescription Drug User Fee Act VII specific to FDA user fees.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--To amend title XVIII of the Social Security Act to provide for coverage and payment of Alpha-1 Antitrypsin Deficiency Disorder treatment under part B of such title, and for other purposes. Coverage for alpha 1 proteinase inhibitor and its administration in the home under Medicare Part B. S 1281, HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act--Medicare Part D restructure, direct negotiation of Medicare pricing, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in a scaled back version of BBBA.

Education efforts surrounding hemophilia B and a new gene therapy treatment that CSL Behring submitted to FDA for licensure HR 5376--Inflation Reduction Act--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of Build Back Better Act. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of Prescription Drug User Fee Act VII specific to FDA user fees.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.

HR 3--Elijah E. Cummings Lower Drug Costs Now Act--Medicare Part D restructure, reference pricing, direct negotiation of Medicare pricing HR 3808--The Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S 1281; HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 3--Elijah E. Cummings Lower Drug Costs Now Act--Medicare Part D restructure, reference pricing, direct negotiation of Medicare pricing HR 3808--The Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S 1281; HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 5376--Build Back Better Act--Medicare Part D restructure, direct negotiation of Medicare pricing, restriction on use of orphan drug tax credit HR 3808--Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S. 1281, HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 3--Elijah E. Cummings Lower Drug Costs Now Act--Medicare Part D restructure, reference pricing, direct negotiation of Medicare pricing HR 3808--The Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S 1281; HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 3--Elijah E. Cummings Lower Drug Costs Now Act--Medicare Part D restructure, reference pricing, direct negotiation of Medicare pricing HR 3808--The Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S 1281; HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 5376--Build Back Better Act--Medicare Part D restructure, direct negotiation of Medicare pricing, restriction on use of orphan drug tax credit HR 3808--Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S. 1281, HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 3--Elijah E. Cummings Lower Drug Costs Now Act--Medicare Part D restructure, reference pricing, direct negotiation of Medicare pricing HR 3808--The Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S 1281; HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 3--Elijah E. Cummings Lower Drug Costs Now Act--Medicare Part D restructure, reference pricing, direct negotiation of Medicare pricing HR 3808--The Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S 1281; HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 5376--Build Back Better Act--Medicare Part D restructure, direct negotiation of Medicare pricing, restriction on use of orphan drug tax credit HR 3808--Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S. 1281, HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 5376--Build Back Better Act--Medicare Part D restructure, direct negotiation of Medicare pricing, restriction on use of orphan drug tax credit HR 3808--Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S. 1281, HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 3--Elijah E. Cummings Lower Drug Costs Now Act--Medicare Part D restructure, reference pricing, direct negotiation of Medicare pricing HR 3808--The Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S 1281; HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 3--Elijah E. Cummings Lower Drug Costs Now Act--Medicare Part D restructure, reference pricing, direct negotiation of Medicare pricing HR 3808--The Medicare IVIG Access Enhancement Act--Coverage for Intravenous immune globulin in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. S 1281; HR 3468--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases.

HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. HR 133--Consolidated Appropriations Act of 2021--Sec. 104. Extension of medicare patient IVIG access demonstration project. Sec. 117. Continued coverage of certain temporary transitional home infusion therapy services. CMS-5528, Interim Final Rule; Most Favored Nation (MFN) Model--Paramaters for definition of qualified drugs for inclusion in the final rule establishing a Most Favored Nation reimbursement model under Medicare Part B Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity HR 748--The "Coronavirus Aid, Relief, And Economic Security ('CARES') Act"--Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency; sought provision to include HR 6218 within CARES Act. Exploration of possibilities to assist with regard to vaccine development and immuno suppressive development specific to national coronavirus response.

H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 6800--The Heroes Act--Seeking to amend the blood donation awareness program language within the CARES Act to include plasma. Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune therapy.

HR 6218, S. 3587--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 2905--Medicare Intravenous Immune Globulin Enhancement Act--Legislation that would create a demonstration home infusion benefit under Medicare Part B for intravenous immune globulin when used in the treatment of chronic inflammatory dymyelinating polyneuropathy. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune globulin therapy. S. 3129--Lower Costs, More Cures Act of 2019--Drug Pricing provisions included in presidential executive orders versus the policies put forward in legislation such as S. 3129 Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity HR 748--The "Coronavirus Aid, Relief, And Economic Security ('CARES') Act"--Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency; sought provision to include HR 6218 within CARES Act. Exploration of possibilities to assist with regard to vaccine development and immuno suppressive development specific to national coronavirus response.

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity HR 748--The "Coronavirus Aid, Relief, And Economic Security ('CARES') Act"--Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency; sought provision to include HR 6218 within CARES Act. Exploration of possibilities to assist with regard to vaccine development and immuno suppressive development specific to national coronavirus response.

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity HR 748--The "Coronavirus Aid, Relief, And Economic Security ('CARES') Act"--Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency; sought provision to include HR 6218 within CARES Act. Exploration of possibilities to assist with regard to vaccine development and immuno suppressive development specific to national coronavirus response.

HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. HR 133--Consolidated Appropriations Act of 2021--Sec. 104. Extension of medicare patient IVIG access demonstration project. Sec. 117. Continued coverage of certain temporary transitional home infusion therapy services. CMS-5528, Interim Final Rule; Most Favored Nation (MFN) Model--Paramaters for definition of qualified drugs for inclusion in the final rule establishing a Most Favored Nation reimbursement model under Medicare Part B Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

HR 6218, S. 3587--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 2905--Medicare Intravenous Immune Globulin Enhancement Act--Legislation that would create a demonstration home infusion benefit under Medicare Part B for intravenous immune globulin when used in the treatment of chronic inflammatory dymyelinating polyneuropathy. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune globulin therapy. S. 3129--Lower Costs, More Cures Act of 2019--Drug Pricing provisions included in presidential executive orders versus the policies put forward in legislation such as S. 3129 Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 6800--The Heroes Act--Seeking to amend the blood donation awareness program language within the CARES Act to include plasma. Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune therapy.

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity HR 748--The "Coronavirus Aid, Relief, And Economic Security ('CARES') Act"--Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency; sought provision to include HR 6218 within CARES Act. Exploration of possibilities to assist with regard to vaccine development and immuno suppressive development specific to national coronavirus response.

H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 6800--The Heroes Act--Seeking to amend the blood donation awareness program language within the CARES Act to include plasma. Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune therapy.

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity HR 748--The "Coronavirus Aid, Relief, And Economic Security ('CARES') Act"--Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency; sought provision to include HR 6218 within CARES Act. Exploration of possibilities to assist with regard to vaccine development and immuno suppressive development specific to national coronavirus response.

HR 6218, S. 3587--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 2905--Medicare Intravenous Immune Globulin Enhancement Act--Legislation that would create a demonstration home infusion benefit under Medicare Part B for intravenous immune globulin when used in the treatment of chronic inflammatory dymyelinating polyneuropathy. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune globulin therapy. S. 3129--Lower Costs, More Cures Act of 2019--Drug Pricing provisions included in presidential executive orders versus the policies put forward in legislation such as S. 3129 Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. HR 133--Consolidated Appropriations Act of 2021--Sec. 104. Extension of medicare patient IVIG access demonstration project. Sec. 117. Continued coverage of certain temporary transitional home infusion therapy services. CMS-5528, Interim Final Rule; Most Favored Nation (MFN) Model--Paramaters for definition of qualified drugs for inclusion in the final rule establishing a Most Favored Nation reimbursement model under Medicare Part B Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity HR 748--The "Coronavirus Aid, Relief, And Economic Security ('CARES') Act"--Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency; sought provision to include HR 6218 within CARES Act. Exploration of possibilities to assist with regard to vaccine development and immuno suppressive development specific to national coronavirus response.

HR 6218, S. 3587--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 2905--Medicare Intravenous Immune Globulin Enhancement Act--Legislation that would create a demonstration home infusion benefit under Medicare Part B for intravenous immune globulin when used in the treatment of chronic inflammatory dymyelinating polyneuropathy. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune globulin therapy. S. 3129--Lower Costs, More Cures Act of 2019--Drug Pricing provisions included in presidential executive orders versus the policies put forward in legislation such as S. 3129 Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity HR 748--The "Coronavirus Aid, Relief, And Economic Security ('CARES') Act"--Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency; sought provision to include HR 6218 within CARES Act. Exploration of possibilities to assist with regard to vaccine development and immuno suppressive development specific to national coronavirus response.

HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. HR 133--Consolidated Appropriations Act of 2021--Sec. 104. Extension of medicare patient IVIG access demonstration project. Sec. 117. Continued coverage of certain temporary transitional home infusion therapy services. CMS-5528, Interim Final Rule; Most Favored Nation (MFN) Model--Paramaters for definition of qualified drugs for inclusion in the final rule establishing a Most Favored Nation reimbursement model under Medicare Part B Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

HR 6218, S. 3587--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 2905--Medicare Intravenous Immune Globulin Enhancement Act--Legislation that would create a demonstration home infusion benefit under Medicare Part B for intravenous immune globulin when used in the treatment of chronic inflammatory dymyelinating polyneuropathy. HR 7839--Continuing Access to In-Home IVIG Act--Legislation that would extend the home infusion demonstration project under Medicare Part B for intravenous immune globulin when used in the treatment of primary immune deficiency. Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune globulin therapy. S. 3129--Lower Costs, More Cures Act of 2019--Drug Pricing provisions included in presidential executive orders versus the policies put forward in legislation such as S. 3129 Raising general awareness about the need and importance of plasma donation - highlighting how there has been a downturn in plasma donation due to COVID and the importance of plasma for manufacturing rare disease therapies

H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HR 6218, S. 3587--Preserving Patient Access to Home Infusion Act--Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 6800--The Heroes Act--Seeking to amend the blood donation awareness program language within the CARES Act to include plasma. Sought provision seeking inclusion of temporary Medicare Part B home infusion during period of national healthy emergency Raising awareness regarding COVID-19 and the potential for convalescent plasma to be used in the creation of a hyper-immune therapy.

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity

HR 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self administered drug lists by Medicare contractors. Advanced Notice of Proposed Rulemaking on International Pricing Index S. 474 (Senate SPIKE Act), HR 2113 (House STAR Act), HR 2296 (House FAIR Act)--Drug Pricing Transparency reporting requirements Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self-administered drug lists by Medicare contractors.

H.R. 3/S. 2543--Lower Drug Costs Now Act; Prescription Drug Pricing Reduction Act; Administration Advance Notice of Proposed Rulemaking on International Pricing Index; International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. H.R. 2296--METRIC Act--Drug Price transparency reporting requirements

HR 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self administered drug lists by Medicare contractors. Advanced Notice of Proposed Rulemaking on International Pricing Index S. 474 (Senate SPIKE Act), HR 2113 (House STAR Act), HR 2296 (House FAIR Act)--Drug Pricing Transparency reporting requirements Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self-administered drug lists by Medicare contractors.

HR 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self administered drug lists by Medicare contractors. Advanced Notice of Proposed Rulemaking on International Pricing Index S. 474 (Senate SPIKE Act), HR 2113 (House STAR Act), HR 2296 (House FAIR Act)--Drug Pricing Transparency reporting requirements Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self-administered drug lists by Medicare contractors.

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity

H.R. 3/S. 2543--Lower Drug Costs Now Act; Prescription Drug Pricing Reduction Act; Administration Advance Notice of Proposed Rulemaking on International Pricing Index; International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. H.R. 2296--METRIC Act--Drug Price transparency reporting requirements

H.R. 3/S. 2543--Lower Drug Costs Now Act; Prescription Drug Pricing Reduction Act; Administration Advance Notice of Proposed Rulemaking on International Pricing Index; International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. H.R. 2296--METRIC Act--Drug Price transparency reporting requirements

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity

H.R. 3/S. 2543--Lower Drug Costs Now Act; Prescription Drug Pricing Reduction Act; Administration Advance Notice of Proposed Rulemaking on International Pricing Index; International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. H.R. 2296--METRIC Act--Drug Price transparency reporting requirements

H.R. 3--Lower Drug Costs Now Act H.R. 19--Lower Costs, More Cures Act of 2019 S. 2543--Prescription Drug Pricing Reduction Act Administration Advance Notice of Proposed Rulemaking on International Pricing Index International Pricing Index, Inflation Cap Medicare Rebates H.R. 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for product and administration of durable medical equipment administered drugs (subcutaneous immune globulin specifically) that are listed on self administered drug lists by Medicare contractors. HR 4712--Fairness in Orphan Drug Exclusivity Act--Clarifying the definition of orphan drug exclusivity

HR 2905--Medicare IVIG Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self administered drug lists by Medicare contractors. Advanced Notice of Proposed Rulemaking on International Pricing Index S. 474 (Senate SPIKE Act), HR 2113 (House STAR Act), HR 2296 (House FAIR Act)--Drug Pricing Transparency reporting requirements Allowance of reimbursement for administration of durable medical equipment administered drugs that are listed on self-administered drug lists by Medicare contractors.

H.R. 3178--Medicare Part B Improvement Act of 2017--Home infusion provision for DME administered drugs incorporated within the budget deal Preserving Access to Orphan Therapies Act--Exploration of fine tuning orphan drug exclusion from the annual pharmaceutical fee Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.)

H.R. 4724--The Medicare IVIG Access Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.) as part of Administration drug pricing blueprint and request for information. CMS memo re: Medicare Advantage plans authorized to employ step therapy for Part B drugs--Educating congressional staff as to the access concerns this new policy will have for patients reliant on Part B therapies Resolution to Affirm the Importance of the Orphan Drug Act--Building support for introduction of a resolution to affirm the importance of the Orphan Drug Act

H.R. 4724--The Medicare IVIG Access Enhancement Act--Lobbied in support of this legislation that would create a home infusion benefit under Medicare Part B for IVIG when used in the treatment of CIDP. Preserving Access to Orphan Drugs Act--Exploration of fine tuning orphan drug exclusion from the annual pharmaceutical fee Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.) as part of Administration drug pricing blueprint and request for information.

H.R. 4724--The Medicare IVIG Access Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.) as part of Administration drug pricing blueprint and request for information. CMS memo re: Medicare Advantage plans authorized to employ step therapy for Part B drugs--Educating congressional staff as to the access concerns this new policy will have for patients reliant on Part B therapies NIH Appropriations funding/DoD Medical Research funding - specific to hereditary angioedema FY 2019 NIH Appropriations - seeking congressional letter identifying NIH funding spent on hereditary angioedema/maintaining hereditary angioedema on the list of conditions for the Dept. of Defense Peer Reviewed Medical Research Program Resolution to Affirm the Importance of the Orphan Drug Act--Building support for introduction of a resolution to affirm the importance of the Orphan Drug Act

H.R. 7324--Preserving Access to Orphan Drugs Act--Orphan Drugs Exclusion from the Branded Annual Pharmaceutical Fee

Preserving Access to Orphan Drugs Act (HR 2315/S1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S.1128) Orphan Drug Tax Credit - highlighting its importance in orphan product development for treatment of rare diseases

Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S.1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S.1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S.1128) Orphan Drug Tax Credit - highlighting its importance in orphan product development for treatment of rare diseases

Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit

Preserving Access to Orphan Drugs Act (HR 2315/S1128) 21st Century Cures advocacy with House Energy & Commerce Committee Preservation of the Orphan Drug Tax Credit

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701); H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.

Medicare Patient IVIG Access Act (S. 701) H.R. 3590, Patient Protection and Affordable Care Act, provisions regarding pharmaceutical fees; H.R. 4872, Health Care and Education Reconciliation Act, provisions concerning Medicaid rebates, orphan drugs; H.R. 4813, to provide for insurance reform, provisions concerning Medicaid rebates, orphan drugs.